← Back to Search

Mitotic Inhibitor

Paclitaxel for Esophageal Cancer

Phase 2
Waitlist Available
Research Sponsored by Theradex
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Performance status: ECOG 0-2
The bulk of the tumor must involve the esophagus or gastroesophageal (GE) junction (for tumors extending between the GE junction into the proximal stomach)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying how well paclitaxel works in treating patients with esophageal cancer.

Who is the study for?
This trial is for adults with esophageal cancer that has spread, come back, or can't be removed by surgery. Participants must not be pregnant or nursing and should use contraception if fertile. They shouldn't have serious heart issues, infections, a history of severe drug allergies (specifically to Cremophor), other cancers within the last 5 years (with some exceptions), brain or bone-only metastases, significant blood disorders, liver/kidney disease beyond set limits, congestive heart failure, or certain neurological conditions.Check my eligibility
What is being tested?
The study is testing the effectiveness of a chemotherapy drug called paclitaxel in patients with advanced esophageal cancer. It's a Phase II trial which means it focuses on how well paclitaxel works and further evaluates its safety. Patients will receive this medication to see if it can stop their tumor cells from growing and ultimately shrink the tumors.See study design
What are the potential side effects?
Paclitaxel may cause side effects like allergic reactions due to an ingredient called Cremophor; low blood cell counts leading to increased infection risk and bleeding problems; nerve damage causing numbness or pain; muscle and joint pain; nausea; hair loss; fatigue; and potential heart complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am able to get out of my bed or chair and move around.
Select...
My cancer mainly affects my esophagus or where my stomach meets my esophagus.
Select...
I am 18 years old or older.
Select...
My cancer is a type of esophageal cancer that cannot be removed by surgery.
Select...
I had skin cancer treated with the goal of curing it.
Select...
My cervical cancer was treated with the intent to cure.
Select...
My cancer can be measured or seen on tests.
Select...
I do not have any serious infections or illnesses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

TheradexLead Sponsor
33 Previous Clinical Trials
1,432 Total Patients Enrolled
David Paul Kelsen, MDStudy ChairMemorial Sloan Kettering Cancer Center
5 Previous Clinical Trials
74 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current openings for patients in this clinical trial?

"Unfortunately, this study is not currently looking for candidates. Although the last update was on July 23rd, 2008, it was originally posted September 1st, 1997. There are 387 other trials that patients may be eligible for."

Answered by AI

What are the associated risks of this treatment?

"As this is a Phase 2 trial, meaning there is only preliminary data supporting safety and none for efficacy, the treatment received a score of 2."

Answered by AI

In how many different medical clinics is this research study being conducted today?

"In addition to other locations, this trial is being conducted out of Cancer Center of Southern Alabama in Mobile, Alabama, Loma Linda University Medical Center in Loma Linda, California, and Florida Cancer Specialists in Fort Myers, Florida."

Answered by AI
~4 spots leftby Mar 2025